About RetInSight

RetInSight GmbH, based in Vienna, was founded in 2020 with the ambition that longevity should not come at the expense of vision loss. We aim to enable people to maintain their full vision in order to preserve their quality of life and lifelong autonomy.

Therefore, we are developing transformative AI-based software solutions that leverage routine optical coherence tomography (OCT) images to monitor and detect progressive retinal diseases such as GA, neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) – the most important age-related diseases that lead to visual impairments in today’s world.

Our mission is to revolutionize ophthalmology through reliable, affordable and easy-to-use AI-based medical software that enables timely diagnosis, accurate monitoring, and personalized treatment of retinal diseases for anyone, any time and at any location by supporting networked care in ophthalmology with the help of AI technology and digital data.

By bringing together the most advanced technologies in computer science, state-of-the-art clinical expertise as well as medical science, we are optimally positioned to help shape the future of precision medicine.

This image has an empty alt attribute; its file name is Group-2827-1024x508.png

Therapeutic monitoring services for Ophthalmologists

Our AI solutions support the leading OCT devices and can be integrated into diverse ophthalmic software systems, such as PACS and EMR, reducing operational effort and cost, saving time for patient care. As a game changer in retinal disease management, RetInSight develops fully automated cloud-based algorithms to reliably identify, localize and quantify all types of pathologies and relevant biomarkers, e.g. fluid in routine OCT examinations.

Diagnostic screening services for Opticians and Optometrists

In a patient-centric manner, opticians and optometrists may cooperate and benefit from real-time OCT image analysis in a user-friendly and plausible format. Eye care professionals are empowered by an objective, quantifiable and reproducible evaluation of each individual patient‘s condition.


Corinna zur Bonsen-Thomas


Corinna zur Bonsen-Thomas, RetInSight’s managing partner and CEO, is a legal executive with 30 years of experience in senior roles in the global pharmaceutical and medical device industry and with start-ups in digital health focusing on medical software and digital image analysis (including Definiens AG; Smart Reporting GmbH). She has significant experience in structured digital data utilization and transactions.

Corinna is a member of the supervisory board of Abivax, a French listed biotech company.

More InfoLess Info

Dr.-Ing. Amir Sadeghipour


Amir Sadeghipour completed his studies in computer science at the TU Berlin with a focus on ArtificiaI Intelligence and was awarded the “Best Doctoral Dissertation of 2015” at the Technical Faculty of Bielefeld University.

He has over 13 years of experience in research and development of AI methods and 6 years of working experience in the private sector. Amir led the software development at OPTIMA (Medical University of Vienna), developing software and AI algorithms for ophthalmic image analyses. In addition, he served as the Head of IT at the VRC (Vienna Reading Center of the Medical University of Vienna). He represents RetInSight’s technical-scientific competence as Chief Technology Officer responsible for AI research, development and digital ecosystems.

More InfoLess Info

Hans Peter Schwarz, MD, Associate Professor of Medicine


Accomplished healthcare executive with more than 30 years experience in the biopharmaceutical and device industry in VP/SVP roles in Research and Development, Medical Affairs.

More InfoLess Info


  • Univ.-Prof. Dr. Ursula Schmidt-Erfurth
    Professor and Chair, Medical University Vienna, Department of Ophthalmology and Optometry
  • Univ.-Prof. Dr. Sepp Hochreiter
    Director, Institute for Machine Learning, Johannes Kepler University Linz, Austria
  • Dr. Wolfgang Hackel
    CFO Global R&D, Takeda